These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16780615)

  • 21. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
    Weisshorn R; Wappler F; Fiege M; Gerbershagen MU; Kolodzie K; Alberts P; Horn EP; Schulte Am Esch J
    J Clin Anesth; 2004 Aug; 16(5):353-7. PubMed ID: 15374556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience of airway management and tracheal intubation under general anesthesia in patients with scar contracture of the neck.
    Xue FS; Liao X; Li CW; Xu YC; Yang QY; Liu Y; Liu JH; Luo MP; Zhang YM
    Chin Med J (Engl); 2008 Jun; 121(11):989-97. PubMed ID: 18706246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of azumolene on normal and malignant hyperthermia-susceptible skeletal muscle.
    Sudo RT; Carmo PL; Trachez MM; Zapata-Sudo G
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):308-16. PubMed ID: 18047479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No carnitine palmitoyltransferase deficiency in skeletal muscle in 18 malignant hyperthermia susceptible individuals.
    Wieser T; Kraft B; Kress HG
    Neuromuscul Disord; 2008 Jun; 18(6):471-4. PubMed ID: 18430572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complications of anaesthesia in neuromuscular disorders.
    Klingler W; Lehmann-Horn F; Jurkat-Rott K
    Neuromuscul Disord; 2005 Mar; 15(3):195-206. PubMed ID: 15725581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Malignant hyperthermia and the otolaryngologist.
    Chang CY; Scher RL
    Ear Nose Throat J; 2003 Jun; 82(6):433-6. PubMed ID: 12861868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of exposure of malignant hyperthermia non-susceptible patients and their relatives to anaesthetic triggering agents.
    Pollock N; Langton EE; Stowell KM; Bulger TF
    Anaesth Intensive Care; 2011 Sep; 39(5):887-94. PubMed ID: 21970134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Living with the diagnosis of malignant hyperthermia].
    Kato A
    Masui; 2002 Nov; 51(11):1280-4. PubMed ID: 12481461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Malignant hyperthermia and day stay surgery.
    Pollock N; Langton E; McDonnell N; Tiemessen J; Stowell K
    Anaesth Intensive Care; 2006 Feb; 34(1):40-5. PubMed ID: 16494148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safe duration of postoperative monitoring for malignant hyperthermia susceptible patients.
    Pollock N; Langtont E; Stowell K; Simpson C; McDonnell N
    Anaesth Intensive Care; 2004 Aug; 32(4):502-9. PubMed ID: 15675210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The anaesthetic management of patients with congenital insensitivity to pain with anhidrosis.
    Rozentsveig V; Katz A; Weksler N; Schwartz A; Schilly M; Klein M; Gurman GM
    Paediatr Anaesth; 2004 Apr; 14(4):344-8. PubMed ID: 15078381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endoscopic transforaminal discectomy for recurrent lumbar disc herniation: a prospective, cohort evaluation of 262 consecutive cases.
    Hoogland T; van den Brekel-Dijkstra K; Schubert M; Miklitz B
    Spine (Phila Pa 1976); 2008 Apr; 33(9):973-8. PubMed ID: 18427318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-treatment complications of soft tissue tumours.
    Shapeero LG; De Visschere PJ; Verstraete KL; Poffyn B; Forsyth R; Sys G; Uyttendaele D
    Eur J Radiol; 2009 Feb; 69(2):209-21. PubMed ID: 19101106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malignant hyperthermia and central core disease causative mutations in Swedish patients.
    Broman M; Islander G; Müller CR; Ranklev-Twetman E
    Acta Anaesthesiol Scand; 2007 Jan; 51(1):50-3. PubMed ID: 17081152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant hyperthermia during general anesthesia: medicolegal considerations.
    Paladino TR
    Leg Med Annu; 1975; ():263-71. PubMed ID: 1221238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia.
    Anderson AA; Brown RL; Polster B; Pollock N; Stowell KM
    Anesthesiology; 2008 Feb; 108(2):208-15. PubMed ID: 18212565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suspected malignant hyperthermia in a child with laminin alpha2 (merosin) deficiency in the absence of a triggering agent.
    Shukry M; Guruli ZV; Ramadhyani U
    Paediatr Anaesth; 2006 Apr; 16(4):462-5. PubMed ID: 16618304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized.
    Halsall PJ; Cain PA; Ellis FR
    Br J Anaesth; 1979 Oct; 51(10):949-54. PubMed ID: 518796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuromuscular and mitochondrial disorders: what is relevant to the anaesthesiologist?
    Driessen JJ
    Curr Opin Anaesthesiol; 2008 Jun; 21(3):350-5. PubMed ID: 18458553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Reposition of nose fractures under local or general anaesthesia. A retrospective patient satisfaction survey].
    Koch KU; Gano L; Kjeldsen AD
    Ugeskr Laeger; 2007 Jun; 169(24):2322-5. PubMed ID: 17594850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.